Product Name
MYBPC3, siRNA
Full Product Name
MYBPC3 siRNA (Human)
Product Synonym Names
Myosin-binding protein C. cardiac-type; Cardiac MyBP-C; C-protein. cardiac muscle isoform
Product Gene Name
MYBPC3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q14896
Specificity
MYBPC3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MYBPC3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MYBPC3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MYBPC3 sirna
siRNA to inhibit MYBPC3 expression using RNA interference
Applications Tested/Suitable for MYBPC3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MYBPC3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000247.2
[Other Products]
NCBI GenBank Nucleotide #
NM_000256.3
[Other Products]
UniProt Primary Accession #
Q14896
[Other Products]
UniProt Secondary Accession #
Q16410; Q6R2F7; Q9UE27; Q9UM53; A5PL00[Other Products]
UniProt Related Accession #
Q14896[Other Products]
Molecular Weight
140,703 Da
NCBI Official Full Name
myosin-binding protein C, cardiac-type
NCBI Official Synonym Full Names
myosin binding protein C, cardiac
NCBI Official Symbol
MYBPC3 [Similar Products]
NCBI Official Synonym Symbols
FHC; CMH4; CMD1MM; LVNC10; MYBP-C
[Similar Products]
NCBI Protein Information
myosin-binding protein C, cardiac-type
UniProt Protein Name
Myosin-binding protein C, cardiac-type
UniProt Synonym Protein Names
C-protein, cardiac muscle isoform
Protein Family
Myosin-binding protein
UniProt Gene Name
MYBPC3 [Similar Products]
UniProt Synonym Gene Names
Cardiac MyBP-C [Similar Products]
UniProt Entry Name
MYPC3_HUMAN
NCBI Summary for MYBPC3
MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3, the cardiac isoform, is expressed exclussively in heart muscle. Regulatory phosphorylation of the cardiac isoform in vivo by cAMP-dependent protein kinase (PKA) upon adrenergic stimulation may be linked to modulation of cardiac contraction. Mutations in MYBPC3 are one cause of familial hypertrophic cardiomyopathy. [provided by RefSeq, Jul 2008]
UniProt Comments for MYBPC3
MYBPC3: Thick filament-associated protein located in the crossbridge region of vertebrate striated muscle a bands. In vitro it binds MHC, F-actin and native thin filaments, and modifies the activity of actin-activated myosin ATPase. It may modulate muscle contraction or may play a more structural role. Belongs to the immunoglobulin superfamily. MyBP family.
Protein type: Myosin-binding
Chromosomal Location of Human Ortholog: 11p11.2
Cellular Component: sarcomere; striated muscle thick filament; cytosol; A band
Molecular Function: identical protein binding; ATPase activator activity; myosin binding; structural constituent of muscle; metal ion binding; titin binding; actin binding; myosin heavy chain binding
Biological Process: heart morphogenesis; positive regulation of ATPase activity; regulation of heart rate; regulation of muscle filament sliding; regulation of striated muscle contraction; ventricular cardiac muscle morphogenesis; sarcomere organization; cell adhesion; myosin filament assembly; cardiac muscle contraction; muscle filament sliding
Disease: Left Ventricular Noncompaction 10; Cardiomyopathy, Familial Hypertrophic, 4
Research Articles on MYBPC3
1. Gene-specific severity of cardiac abnormalities may underlie differences in disease onset and suggests that early initiation of metabolic treatment may be beneficial, in particular, in myosin heavy chain (MYH7) mutation carriers
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
